Efficacy and Safety of Probiotic Strain Bifidobacterium Animalis Subsp. Lactis CECT 8145 Probiotic in the Reduction of Abdominal/Visceral Fat in Overweight and Obese Patients: Double-blind, Randomised, Placebo-controlled Trial
Efficacy and Safety of Probiotic Strain Bifidobacterium Animalis Subsp. Lactis CECT 8145 Probiotic in the Reduction of Abdominal/Visceral Fat in Overweight and Obese Patients: Double-blind, Randomised, Placebo-controlled Trial
The study's main objective is to investigate the effect of a probiotic (live bacteria), postbiotic (heat-treated bacteria) on obesity parameters.
Investigation of the efficacy of probiotics as adjuvant in the management of overweight and obesity. Specifically, in the reduction of abdominal/visceral adipose tissue.
Inclusion Criteria:
Male and female subjects from 18 to 65 years old.
Established diagnosis of overweight (BMI ≥ 25 and up to 34.9)
Waist circumference ≥ 102 cm for men
Waist circumference ≥ 88 cm for women
Signature of the informed consent letter.
Agreement to comply with the protocol and study restrictions
Exclusion Criteria:
Diagnosed and pharmacologically-treated type 1 or type 2 diabetes
Subjects with serious autoimmune disease, cardiovascular disease, liver dysfunction/disease, kidney dysfunction/disease or chronic disease
Immunosuppression or ongoing therapy causing immunosuppression
Pharmacologically-treated (medication/supplements) hypertension or dyslipidaemia
Subjects consuming antibiotics in the previous 2 months
Subjects consuming probiotics and prebiotics at least 1 month prior to inclusion in the study or during the intervention period.
History of chronic active inflammatory disorders
History of bariatric surgery
History of any chronic gastrointestinal disease (e.g. IBD).
Known hypersensitivity to any ingredients in the active or placebo products.